Press release BoxID: 877918 (ARTES Biotechnology GmbH)
  • ARTES Biotechnology GmbH
  • Elisabeth-Selbert-Str. 9
  • 40764 Langenfeld
  • Contact person
  • Melanie Piontek
  • +49 (2173) 2758712

ARTES receives French Research Tax Credit (CIR) Accreditation

ARTES Biotechnology GmbH today announced that it has just obtained governmental approval for 'Crédit d'Impôt Recherche' (CIR) for a three-year period from the French Ministry of Higher Education and Research (MESR)

(PresseBox) (Langenfeld, ) The French R&D tax credit CIR gives French companies the ability to claim tax relief on 30% on all generated costs outsourced to ARTES’ R&D services.

“We are pleased to receive this accreditation and to be approved as valid and reliable R&D provider from the French Ministry”, Dr Michael Piontek, Managing Director of ARTES. “It allows our customers in France to benefit from tax relief of their R&D expenses committed to us and it will help us to tie up our relationships with our present clients in France and to install new collaborations”.

ARTES Biotechnology is globally active as R&D company specialized in developing biopharmaceutical and vaccine production processes.

The company operates worldwide from its 850m2 S1 facilities in Langenfeld, from where it also offers cell line engineering based on yeast (Hansenula polymorpha) and bacterial (E. coli and Bacillus) expression platforms, lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support

Website Promotion

ARTES Biotechnology GmbH

ARTES is a pharmaceutical technology provider specialized in recombinant protein production, process and vaccine development from microbial expression systems and markets the unique METAVAX® (dHepB-VLP) technology in combination with yeast expression. ARTES platform is applicable for large and multimeric antigens and is able to create chimeric VLPs. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850-sqm S1 facilities in Langenfeld..